TickerTalks
Browse all tickers →
TickerTalks›$WUXIF
WUWUXIF

WuXi AppTec Co., Ltd.

$WUXIF·$77B·Medical - Diagnostics & Research·Healthcare
$25.85+7.5%YTD+52.8%1Y+72.3%
Price updated 41d ago·X counts updated 41d ago
WUWUXIF
$WUXIFWuXi AppTec Co., Ltd.
$25.85+7.51%0 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $WUXIF on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

0X posts · last 7 days
No mention history yet

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $WUXIF — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersAcceleratingAI verdict · as of 2026-09-04

The move is getting stronger, with heavier trading behind it.

Chinese CDMO WuXi AppTec up 60% in a year with big beats, DoD complaint, and rising interim dividend.

WuXi AppTec is a Chinese contract research and manufacturing organization (CDMO) serving global pharma customers — a mega-cap ($62B) that has been re-rated on both operational strength and geopolitical developments.

  • Stock at $24.05, up ~53% year-to-date and ~60% over twelve months, sitting at 74% of the 52-week range and 11% above the 50-day moving average — a solid uptrend.
  • EPS beats have been strong — Q2 at $0.32 vs $0.23 expected (+39.2%), Q1 at $0.23 vs $0.18 (+30.5%), Q4 2025 at $0.37 vs $0.38 (-3.9%), Q3 2025 at $0.17 vs $0.15 (+13.9%) — three of four beat significantly.
  • The concrete geopolitical event: WuXi AppTec filed a complaint against the U.S. Department of Defense for linking it to Chinese military — real legal pushback on the Biosecure-Act-related restrictions.
  • Capital-return signal: WuXi AppTec increased its interim dividend to RMB 1.51 billion — real capital-return discipline.
  • Fundamentals are strong: PE 18.7, gross margin 52%, operating margin 42% (very high), ROIC 18%, ROE 27%, FCF yield 3.9%, debt/equity 0.18 (low), EV/EBITDA 11.
  • Revenue growing sequentially in yuan ($12B-$16.4B CNY range) — real operational base.
  • Analyst forward estimates step meaningfully in yuan — 2026 EPS 6.08 CNY, 2027 7.11, 2028 8.28 — supportive multi-year growth.
  • Volume multiplier 1.85 — real institutional flow.

Beta 0.49 is defensive; the swing factor is US Biosecure Act developments and Chinese-CDMO customer-relationship stability.

What to watch: October 28 earnings ($0.31 EPS consensus), Biosecure Act legislative and legal developments, WuXi vs DoD complaint proceedings, and CDMO customer-retention metrics.

On the calendar: 2026-10-28 earnings

no x sentimentadrchina risklegal overhang

Read the AI verdict on $WUXIF

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Chinese pharmaceutical contract research and manufacturing organization (CRO/CDMO) serving global drug discovery and production pipelines.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $WUXIF.

Medical - Diagnostics & Research · Healthcare

Genetic testing, liquid biopsy, and multi-cancer early detection (MCED) platforms are growing through direct-to-consumer and employer wellness channels; reimbursement coverage expansion by CMS and commercial payers is the adoption bottleneck. Lab volume normalization post-COVID is complete; growth is now driven by novel test launches and test menu expansion for chronic disease management.

What this means for $WUXIF

Partial — upstream oil & gas exposure ties to commodity price cycle; WuXi AppTec Co.

Industry benchmark

20-name peer basket
+35.7%YTD
+53.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
18.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
17.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
42.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
6.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
27.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
52.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 3, 2026$0.32$0.23+39.2%
Q1 2026Apr 27, 2026$0.23$0.18+30.5%
Q4 2025Mar 23, 2026$0.37$0.38-3.9%
Q3 2025Oct 27, 2025$0.17$0.15+13.9%
Next earningsWed, Oct 28·consensus EPS $0.31

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$16.4B+47.1%55.8%47.2%$2.24—
Q1 FY26$12.4B+28.8%50.4%45.2%$1.59$2.4B
Q4 FY25$12.6B+9.2%50.3%39.6%$2.48$3.8B
Q3 FY25$12.0B+15.1%49.8%38.3%$1.21$2.7B

Forward consensus

5-year forecast · up to 19 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$53.3B$51.7B – $56.4B$6.08$5.79 – $6.9019
FY27$62.3B$59.6B – $71.1B$7.11$6.77 – $8.0519
FY28$71.9B$69.3B – $79.3B$8.28$7.88 – $9.388
FY29$85.6B$82.4B – $94.3B$9.74$9.27 – $11.0410
FY30$100.2B$96.5B – $110.4B$11.34$10.80 – $12.8516

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.—Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.87%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+16.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+59.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 2.5B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.495-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.ListedOTCListed on an over-the-counter market (PNK / OTCQB / OTCQX), not a major exchange. Lower disclosure requirements and thinner liquidity.

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billionprnewswire.com·46d agoContrasting Sotera Health (NASDAQ:SHC) & WuXi AppTec (OTCMKTS:WUXIF)defenseworld.net·56d agoWuXi AppTec files complaint against U.S. DoD for linking it to Chinese militaryreuters.com·126d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPR

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NEO$A$ILMN$TMO$GH$NTRA$DHR$GRAL
Voices on X · last 7 days

No standout posts about $WUXIF on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport